

**Supplementary Table 1.** Comparison of clinical and laboratory characteristics according to the presence of PAH

Characteristics	Non PAH (n = 28)	Confirmed PAH (n = 4)
<b>Demographics</b>		
Female, n (%)	24 (85.7)	4 (100)
Age (years)	53.0 (34–71)	58.5 (40–73)
Body mass index (kg/m <sup>2</sup> )	22.9 (15.8–28.5)	19.8 (16.8–22.9)
<b>SSc characteristics</b>		
Disease duration (month)	73.0 (3–264)	146.3 (120–192)
Subtype, n (%)		
Diffuse	18 (64.3)	3 (75.0)
Limited	10 (35.7)	1 (25.0)
Raynaud's phenomenon, n (%)	28 (100)	4 (100)
Sclerodactyly, n (%)	23 (82.1)	2 (50.0)
Telangiectasia, n (%)	1 (3.6)	1 (25.0)
Digital ulcer, n (%)	6 (21.4)	1 (25.0)
Interstitial lung disease, n (%)	11 (39.3)	3 (75.0)
Reflux symptom, n (%)	20 (71.4)	3 (75.0)
Dyspnea (WHO functional class), n (%)		
0	17 (60.7)	0
1	5 (17.9)	0
2	4 (14.3)	1 (25.0)
3	2 (7.1)	3 (75.0)*
4	0 (0)	0 (0)
<b>Serum markers</b>		
ANA titer	989 (40–1280)	853 (640–1280)
Anti-Scl-70 Ab positivity, n (%)	14/22 (63.6)	2/2 (100.0)
Anti-centromere Ab positivity, n (%)	2/9 (22.2)	0/0
<b>Echocardiographic data</b>		
LVEF (%)	60.6 (57–65)	53.0 (53–53)
TR Vmax (m/s)	2.7 (2.1–3.1)	3.4 (3.2–3.8) <sup>†</sup>
TR Vmax (m/s), n (%)		
≤ 2.8	23 (82.1)	0 (0)
> 2.8 to ≤ 3.4	5 (17.9)	3 (75.0)
> 3.4	0 (0)	1 (25.0)

Patients with suspected PAH who were not confirmed by the right heart catheterization were excluded in this analysis. \**p* value less than 0.05, <sup>†</sup>*p* value less than 0.01. PAH: pulmonary arterial hypertension, SSc: systemic sclerosis, WHO: World Health Organization, ANA: antinuclear antibody, LVEF: left ventricular ejection fraction, TR Vmax: maximal tricuspid regurgitation velocity